Tianjin Lisheng Pharmaceutical Co Ltd Cash Flow Reinvestment Rate
Tianjin Lisheng Pharmaceutical Co Ltd cash flow reinvestment rate. Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a Cash Flow Reinvestment Rate of 0.94x as of December 2025, reinvesting CN¥270.12 Million (capex CN¥20.11 Million plus investments CN¥250.02 Million) from operating cash flow of CN¥287.81 Million. Explore Tianjin Lisheng Pharmaceutical Co Ltd debt service capacity to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Tianjin Lisheng Pharmaceutical Co Ltd (2007–2025)
Cash flow reinvestment rate of Tianjin Lisheng Pharmaceutical Co Ltd from 2007 to 2025. Historical reinvestment intensity for Tianjin Lisheng Pharmaceutical Co Ltd across 19 annual periods. Explore Tianjin Lisheng Pharmaceutical Co Ltd (002393) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.
Tianjin Lisheng Pharmaceutical Co Ltd Cash Flow Reinvestment Rate by Year (2007–2025)
Tianjin Lisheng Pharmaceutical Co Ltd cash flow reinvestment rate by year from 2007 to 2025. Year-by-year capital reinvestment analysis for Tianjin Lisheng Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see 002393 cash flow metrics.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.36x | CN¥163.21 Million | CN¥451.85 Million | CN¥37.46 Million | ▼ -88.4% |
| 2024 | 3.13x | CN¥275.93 Million | CN¥88.26 Million | CN¥53.75 Million | ▲ +19.5% |
| 2023 | 2.62x | CN¥548.18 Million | CN¥209.51 Million | CN¥61.72 Million | ▲ +341.1% |
| 2022 | 0.59x | CN¥196.55 Million | CN¥331.38 Million | CN¥40.91 Million | ▼ -29.1% |
| 2021 | 0.84x | CN¥164.36 Million | CN¥196.34 Million | CN¥88.24 Million | ▼ -37.0% |
| 2020 | 1.33x | CN¥101.41 Million | CN¥76.37 Million | CN¥100.66 Million | ▲ +254.1% |
| 2019 | 0.37x | CN¥100.62 Million | CN¥268.33 Million | CN¥90.46 Million | ▼ -46.8% |
| 2018 | 0.70x | CN¥114.59 Million | CN¥162.69 Million | CN¥104.43 Million | ▲ +109.5% |
| 2017 | 0.34x | CN¥60.25 Million | CN¥179.25 Million | CN¥50.09 Million | ▼ -82.0% |
| 2016 | 1.86x | CN¥323.67 Million | CN¥173.60 Million | CN¥137.20 Million | ▲ +32.1% |
| 2015 | 1.41x | CN¥279.60 Million | CN¥198.13 Million | CN¥204.60 Million | ▼ -64.9% |
| 2014 | 4.02x | CN¥290.65 Million | CN¥72.24 Million | CN¥290.65 Million | ▲ +272.2% |
| 2013 | 1.08x | CN¥313.11 Million | CN¥289.62 Million | CN¥313.11 Million | ▲ +20.8% |
| 2012 | 0.89x | CN¥224.35 Million | CN¥250.72 Million | CN¥224.35 Million | ▼ -27.4% |
| 2011 | 1.23x | CN¥165.94 Million | CN¥134.58 Million | CN¥165.94 Million | ▲ +230.1% |
| 2010 | 0.37x | CN¥69.69 Million | CN¥186.55 Million | CN¥69.69 Million | ▲ +316.4% |
| 2009 | 0.09x | CN¥17.60 Million | CN¥196.14 Million | CN¥17.60 Million | ▼ -82.5% |
| 2008 | 0.51x | CN¥64.86 Million | CN¥126.59 Million | CN¥64.86 Million | ▲ +543.9% |
| 2007 | 0.08x | CN¥13.92 Million | CN¥174.94 Million | CN¥13.92 Million | — |